Degradation versus Aggregation of Misfolded Maltose-binding Protein in the Periplasm of Escherichia coli*

Jean-Michel BettonDagger §, Nathalie SassoonDagger , Maurice HofnungDagger , and Michel Laurent

From the Dagger  Unité de Programmation Moléculaire et de Toxicologie Génétique/CNRS-URA1444, Département des Biotechnologies, Institut Pasteur, 25, rue du Docteur Roux 75015 Paris, France and the  Service d'Imagerie Cellulaire/CNRS-URA D2227, Bâtiment 440, Université Paris-Sud, 91405 Orsay cedex, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The periplasmic fates of misfolded MalE31, a defective folding mutant of the maltose-binding protein, were determined by manipulating two cellular activities affecting the protein folding pathway in host cells: (i) the malEp promoter activity, which is controlled by the transcriptional activator MalT, and (ii) the DegP and Protease III periplasmic proteolytic activity. At a low level of expression, the degradation of misfolded MalE31 was partially impaired in cells lacking DegP or Protease III. At a high level of expression, misfolded MalE31 rapidly formed periplasmic inclusion bodies and thus escaped degradation. However, the manipulated host cell activities did not enhance the production of periplasmic, soluble MalE31. A kinetic competition between folding, aggregation, and degradation is proposed as a general model for the biogenesis of periplasmic proteins.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Among the functions of protein degradation in living cells is the elimination of misfolded proteins with abnormal conformations (1). Because misfolded proteins can induce cellular stress (2), proteolysis is a major component of the highly conserved regulatory heat shock response. Recently, a new heat shock sigma factor, sigma E (or sigma 24), involved in extra-cytoplasmic stresses has been discovered in Escherichia coli (4). In the periplasmic compartment, among many proteases, the DegP (also known as HtrA or Do) protease is the only protease, identified as a heat shock protein, involved in the degradation of misfolded proteins (3, 4). The degP gene, which is under the transcriptional regulation of sigma sigma E, is essential for the survival of E. coli above 42 °C (5).

Our aim is to understand the exact relationships between export and folding of bacterial periplasmic proteins. We are using a model system based on the maltose-binding protein (MalE or MBP) of E. coli. The MalE protein serves as the periplasmic receptor for the high affinity transport of maltose and maltodextrins (6). Because of its key role in maltose transport, correct export and folding of MalE into the periplasm is essential for cells to utilize maltose as a carbon source. This feature facilitated the use of genetic selections for analyzing MalE export (7) and folding (8). MalE is synthesized in the cytoplasm as a precursor protein, preMalE, with an amino-terminal signal sequence. This signal sequence serves to target the precursor protein to the periplasm. As the precursor enters the periplasm, the signal sequence is cleaved off by the signal peptidase. Upon removal of the signal peptide, the protein is released from the membrane into the periplasm and refolds to its native structure. The three-dimensional structure of MalE consists of two discontinuous domains constructed from secondary structural beta alpha beta units surrounding a cleft that forms the binding site for maltose and maltodextrins (9, 10).

We previously identified amino acid substitutions of MalE that are critical for the in vivo folding (11). Among these mutations, the most defective variant, MalE31, corresponds to the double substitution of G32D and I33P in the alpha beta loop connecting the helix I to strand B of the N-domain. In vivo, the MalE31 precursor was correctly exported, based on the kinetics of signal peptide processing, but the defective folding of the mature protein in the periplasm led to the formation of inclusion bodies (11). However, the modified loop, which is apart from the maltose-binding site, did not perturb the maltose-binding affinity of the purified protein, renatured from inclusion bodies. One major physiological consequence for the cells overproducing MalE31 was an increase in sigma E activity, and, hence, DegP synthesis (12). However, this increased level of DegP did not degrade a series of misfolded MalE31 variants (8). In this study, we have examined the production of MalE31 in several protease-deficient strains to clarify these contradictory observations and to specify precisely the different kinetic parameters between folding, aggregation, and degradation of proteins in the periplasm of E. coli.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Bacterial Strains and Plasmids-- The bacterial strains used in this study are listed in Table I. The degP and ptr mutants were constructed by standard P1 transduction (13) of HS2019 (14) using KS474 (6) and SF103 (15) as donors and selecting for resistance to kanamycin and chloramphenicol, respectively. The recA1 allele was introduced by cotransduction with srl::Tn10. All strains carried a non-polar deletion of the chromosomal malE gene (14), and pop6499 gave constitutive, high level expression of the maltose operons because it contained the malTc allele (16). Plasmids pHCME31 and pHCME-I33P are pBR322 derivatives that carry the malE alleles under the control of their own promoters; the MalT-dependent malEp promoter (11). Plasmids pOM82 (pSC101 derivative) and pMDX (pBR322 derivative) encoded the lacZ gene under the control of the malEp promoter (17) and the tac promoter,1 respectively. Plasmid pT31H is a pBR322 derivative of pT1H (18) expressing the malE31 gene under the control of the tac promoter. Plasmid pDelta 709 is a pHCME derivative that carries a deletion of the ribosome binding site and the first 256 codons of the malE gene (19) and was used as a negative control.

Cell Fractionation-- Cultures were grown in LB medium (13) supplemented with 0.1 mg/ml carbenicillin and 0.2% maltose, at 30 °C for 3 h (A600 approx  1). Cells from 10 ml of the culture (5 × 108 cells/ml) were harvested by centrifugation and fractionated by spheroplast preparation as described previously (8). The periplasmic and membrane fractions were analyzed by SDS-polyacrylamide gel electrophoresis (12.5% acrylamide). Proteins were visualized by either Coomassie Blue or silver staining and scanned with a MasterScan I Interpretive densitometer (Scanalytics). Relative steady-state levels of insoluble MalE31 were normalized to the level of the outer membrane protein, OmpA, and the amount of MalE31 in the pop6499 cells was taken as 100%.

Pulse-Chase Experiments-- Cells (pop6499 and pop6590 strains) harboring pHCME31 were grown at 30 °C in M63B1 medium (13) supplemented with 0.4% glycerol, 0.4% maltose, 0.1 mg/ml carbenicillin, and each of the 20 amino acids (40 µg/ml) except methionine and cysteine. Cells were labeled with 60 µCi of [35S]methionine/ml for 2 min and then chased with an excess of unlabeled methionine (2 mg/ml). At various times, 0.1-ml fractions were removed and immediately lysed by boiling with 0.1 ml of 4% SDS gel-loading buffer for 3 min. Lysates were electrophoresed on SDS-polyacrylamide gel electrophoresis (14% acrylamide).

Assay of beta -Galactosidase Activity-- Cells (pop6499 and pop6590 strains) harboring pOM82 or pMDX were grown in M63B1 medium supplemented with 0.4% glycerol, 0.1% casamino acids, and 0.1 mg/ml ampicillin at 30 °C. At an A600 of 0.1, isopropyl-1-thio-beta -D-galactopyranoside (final concentration, 0.1 mM) or maltose (final concentration, 0.2%) was added to the cultures. After 2 h of induction, cells were harvested. and beta -galactosidase activity was determined as described in Miller (13).

Protein Purification-- Strain pop6499, producing either wild-type or variant (MalE31 or MalE-I33P) MalE, was grown at 30 °C in LB medium supplemented with 0.1 mg/ml carbenicillin. The wild-type MalE was released by osmotic shock procedure (20). The MalE31 and MalE-I33P proteins were purified from inclusion bodies after a urea solubilization step as described previously (11). All three proteins were purified by affinity chromatography on a cross-linked amylose column (21). Protein concentrations were determined from the absorbance at 280 nm with an extinction coefficient of epsilon  = 68,750 M-1·cm-1 (11).

In Vitro Refolding Kinetics-- Refolding kinetics were performed by a 101-fold dilution of unfolded MalE variants (10 µM in 4.2 M GdnHCl)2 into a final concentration of 0.04 M GdnHCl, 25 mM Tris-HCl, pH 7.5, at 25 °C. The fluorescence emission intensities were recorded at 345 nm (excitation wavelength, 290 nm) using a Fluoromax spectrofluorometer (Spex). Data were fitted using the non-linear regression analysis program Kaleidagraph (Synergy Software, PCS Inc.).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

To determine the exact susceptibility of misfolded MalE31 to periplasmic degradation, we constructed three isogenic protease-deficient strains lacking either the DegP protease (NS2) or the Protease III (NS6) or both (NS5; Table I). Protease III (also known as Pi), the ptr gene product, is another periplasmic protease involved in the degradation of exported protein fusions (15). The steady-state level of MalE31 in these different protease-deficient strains is shown in parallel with the strain carrying the malTc allele (Fig. 1A). The presence of the malTc allele in the pop6499 strain ensured that the malE31 gene encoded by pHCME31 is expressed at a high and constitutive level, even in absence of maltose. Because no cytoplasmic accumulation and complete processing of the MalE31 precursor were previously reported in this genetic background (11), the preprotein translocase did not limit the periplasmic level of MalE31 under these conditions of high expression. Thus, intracellular distribution between soluble and insoluble fraction is given by cellular fractionation into periplasmic and membrane fractions, respectively. The MalE31 protein was found predominantly in the membrane fraction (Fig. 1A). The level of periplasmic MalE31 was very low, and the protein could be only detected after silver staining the gel. However, although the deficiency of protease and the promoter strength had no effect on the soluble protein, it had pronounced effects on the level of aggregated MalE31. From the membrane fractions, production of aggregated MalE31 ranged from a high level (in strain pop6499) to undetectable (in strain pop6590).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Strains


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Fractionation of soluble and insoluble MalE variants. Cells grown in rich medium containing 0.2% maltose at 30 °C for 3 h were fractionated from spheroplasts. Periplasmic (soluble) and membrane fractions (insoluble), corresponding to 108 bacteria, were separated by SDS-polyacrylamide gel electrophoresis (12.5% acrylamide). The gels were stained with Coomassie Blue or silver-stained. A, strains harboring pHCME31 or pDelta 709 plasmid. B, strains harboring pHCME-I33P or pDelta 709 plasmid.

Previous mutagenesis studies indicated that the extent of periplasmic inclusion body formation varied with the nature of amino acid residues at positions 32 and 33 of MalE (8). The MalE-I33P variant that displayed less severe folding defects than MalE31 had a soluble/insoluble distribution of 40/60 (11). At the steady-state, the periplasmic levels of MalE-I33P were very similar whatever the producing strain (Fig. 1B). Once again, differences were observed only for the aggregated protein sedimenting with membrane fractions (Fig. 2). Although the basal level in pop6590 is higher than for MalE31, insoluble production of MalE-I33P was similarly enhanced in the protease-deficient strains. Increased production in the three protease-deficient strains (NS2, NS5, and NS6) relative to the isogenic pop6590 strain suggests decreased degradation of misfolded MalE31 and MalE-I33P. Although the effects of the degP and ptr mutations were approximately cumulative, DegP deficiency was more effective on the degradation of both misfolded proteins (Fig. 2). However, the greatest amount of insoluble MalE31 was found in the malTc strain (pop6499), even though this strain is degP+, ptr+.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Insoluble production of MalE variants. Relative steady-state levels of insoluble MalE31 and MalE-I33P were determined from densitometric analysis of the gels shown in Fig. 1 and normalized to the level of the outer membrane protein OmpA. The amount of MalE31 or MalEI33P in the pop6499 cells was taken as 100%.

The production level of MalE31 in the pop6590 strain, assessed from both the periplasmic and membrane fractions shown in Fig. 1B, was very low compared with the pop6499 strain. We performed two sets of experiments to test whether the expression of the malE31 gene was poorly induced and/or whether the corresponding protein was correctly synthesized and exported but rapidly degraded.

First, the high level expression of malE31 obtained in the pop6499 strain could stem primarily from the activation of the MalT-dependent promoter. Thus, we quantified the malEp promoter activity in the malT+ (pop6590) and malTc (pop6499) genetic backgrounds using two different transcriptional gene fusions: malEp-lacZ encoded by pOM82 and tac-lacZ encoded by pMDX (Fig. 3A). The synthesis of beta -galactosidase directed from the malEp promoter was 5-fold higher in pop6499 than in pop6590. However, in both strains, transformed by pMDX, the same level of beta -galactosidase activity was measured. This result suggested that translational levels in both strains are similar when a gene is transcribed from a MalT-independent promoter. Further comparisons of these strains were investigated with pT31H, a plasmid expressing malE31 under the control of the tac promoter. The membrane fractions, prepared as described above, showed a similar level of aggregated MalE31 in both strains (Fig. 3B) and confirmed the transcriptional fusion data obtained with pMDX.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Promoter activity in malT+ and malTc strains. A, activity of malEp and tac promoters was tested in the malT+ (pop6590) and malTc (pop6499) strains, harboring either pOM82 (malEp-lacZ) or pMDX (ptac-lacZ) plasmids, respectively. beta -Galactosidase activity (Miller units) was measured in maltose-induced (pOM82) or isopropyl-1-thio-beta -D-galactopyranoside-induced (pMDX) strains using the average of four determinations with their standard deviation. B, expression of the malE31 gene under the control of the tac promoter. pop6590 and pop6499 strains harboring pT31H were fractionated as described in the legend to Fig. 1. Membrane fractions were separated by SDS-polyacrylamide gel electrophoresis and stained with Coomassie Blue. Lane 1, molecular weight standards. Lane 2, pT31H in pop6590. Lane 3, pT31H in pop6499. The bands corresponding to LamB, MalE31, and OmpA are indicated by arrows.

Second, pulse-chase experiments were performed to measure the intracellular stability of MalE31 in both strains (Fig. 4). MalE31 appeared to be rapidly degraded in the malT+ strain; in fact no protein was observed after a 1-min chase (half-life < 30 s). In contrast, the protein showed no degradation in pop6499 after 1 h. From Fig. 4, it is evident that MalE31 is considerably more stable in the malTc strain; this stability can be attributed to the insoluble misfolded protein. Conversely, intracellular degradation appeared to be a major cause of the low level production of MalE31 observed in pop6590 cells.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 4.   Degradation of MalE31 in the pop6590 strain. pop6590 (malT+) and pop6499 (malTc) strains harboring pHCME31 were grown in minimal medium containing 0.4% glycerol and 0.4% maltose at 30 °C. Cells were labeled for 2 min with [35S]methionine and incubated for 0-60 min with an excess of unlabeled methionine. Lane U corresponds to the control plasmid pDelta 709 in pop6499 strain.

Previous transcriptional studies on sigma E activity performed with a fusion of the degP promoter to the lacZ gene has demonstrated that degP transcription is increased in cells overproducing MalE31 (12). However, this increased cellular level of DegP did not degrade the misfolded MalE31, overproduced in the pop6499 strain (8). To test, more directly, the steady-state level of DegP production on MalE31 overproduction in pop6499 and pop6590 cell extracts, we performed an immunoblot analysis with anti-DegP antibodies. Data on Fig. 5A confirmed those obtained previously with the degP-lacZ fusion: the cellular level of DegP increased with the level of insoluble MalE31. However, when cellular fractionation was carried out, the periplasmic amount of DegP did not reflect its level in whole cell extracts. Indeed, DegP was found mainly associated with membrane fractions, and the level of DegP in these insoluble fractions increased with the extend of MalE31 aggregation (Fig. 5B). This result suggests that export of DegP could be blocked in the membrane (if the export pathway is overloaded or partially jammed by the MalE31 precursor) or, alternatively, that DegP coaggregated with misfolded MalE31 in the periplasm. To determine whether the anomalous cellular localization of DegP provoked by the overproduction of MalE31 could be related to an inhibition of the export pathway, the signal sequence processing of DegP precursor was examined by pulse-chase experiments. There was no significant difference in DegP precursor processing observed in pop6499 cells carrying pHCME31 or pDelta 709 (data not shown). Therefore, under overproduction of MalE31, DegP coaggregated with misfolded MalE31 in inclusion bodies.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of overproduced MalE31 on DegP. Fractions from cellular fractionation experiment shown in Fig. 1A were separated by SDS-polyacrylamide gel electrophoresis, and immunoblot analysis of the gel was performed by using a rabbit antibody directed against DegP. A, whole cell extracts. B, periplasmic and membrane fractions. Lanes 1, pHCME31 in pop6590. Lanes 2, pHCME31 in NS2. Lanes 3, pHCME31 in pop6499. Lanes 4, pDelta 709 in pop6499.

Several studies carried out on various proteins produced in the cytoplasm of E. coli supported a correlation of thermodynamic stability with the extent of inclusion body formation (22-24). The results described here suggest that instead of thermodynamic stability, dynamic folding properties of the newly translocated protein would better reflect the final distribution among alternative pathways. We therefore determined whether the amino acid substitutions at positions 32 and 33 had altered the folding rate of MalE. The refolding process of the wild-type and variant proteins after denaturation in 4 M GdnHCl, as monitored by the fluorescence of tryptophan residues, appeared to be at least biphasic (Fig. 6). The first phase was too fast to be analyzed by manual mixing (dead time of 10 s). However, this phase was detected because its amplitude accounted for 40% of the total signal recorded between native and denatured proteins. The remainder of the change in fluorescence accompanying refolding (60%) was attributed to a slow phase with a rate constant that varies between the different MalE variants (Table II). The final renaturation yields of the MalE variants, reported in Table II, reflected well their intrinsic tendency to misfold. The MalE-I33P protein purified from the soluble periplasmic fraction (by osmotic shock) displayed similar refolding kinetic parameters to those of the protein purified from inclusion bodies (data not shown). It is interesting to note the correlation between the refolding rate and the extent of corresponding soluble MalE protein in the periplasmic fractions (Table II).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   In vitro refolding kinetics of MalE variants. Refolding kinetics were monitored by increased tryptophan fluorescence, excitation at 290 nm, and emission at 345 nm. Refolding was initiated by mixing proteins (10 µM) denaturated in 4.2 M GdnHCl, 25 mM Tris-HCl, pH 7.5, with 100 volumes of 25 mM Tris-HCl at 25 °C. Fluorescence intensities of the unfolding proteins in 4.2 M GdnHCl and native proteins were taken as 0 and 100%, respectively. The solid lines are fits of the data to a single exponential term.

                              
View this table:
[in this window]
[in a new window]
 
Table II
In vitro refolding of MalE variants

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

This work was initiated to delineate the determinants of the fate of misfolded proteins, dictated by the interplay between host cell characteristics and protein folding parameters. By modulating cellular factors involved in the folding pathway of misfolded variants of MalE, we showed that: (i) at low level promoter activity, the protein was rapidly degraded by at least two known periplasmic proteases, DegP and Protease III; (ii) at high level promoter activity, the protein aggregated and formed inclusion bodies; and (iii) the level of soluble protein depended neither on promoter activity nor on proteolytic activity but could be determined by the ratio of rate constants governing the competition between misfolding and folding.

In regards to periplasmic degradation, the high production level of MalE31 in pop6499 had two important consequences. First, increased amounts of aggregating species increases the formation of inclusion bodies, the compact nature of which renders them resistant to proteases. Such a protective effect is well documented in the literature (25). Second, although overproduction of misfolded MalE31 increased the rate of DegP synthesis via the sigma E response, the majority of that increased amount of protease was localized in the insoluble fraction. Because DegP is intimately involved in the degradation of misfolded proteins in the periplasm (3), it is conceivable that DegP co-aggregated with misfolded MalE31 during the formation of inclusion bodies.

A working model for the periplasmic fates of the newly translocated protein is presented in Fig. 7 and used for simulations. Although some aspects are hypothetical, the main features of the model are as follows: (i) The single folding step involved in the formation of the native structure is competing with the initial misfolding step leading to aggregation or degradation. (ii) The misfolding species would originate from the formation of a wrong chain conformation (as an incorrect isomeric state of a peptidyl-prolyl peptide, see below). This isomerization step is followed either by further association steps involved in the formation of inclusion bodies (high order reaction) or by a degradation step of this partially structured and misfolded intermediate. (iii) Although the misfolded protein is assumed to be the only conformation of the protein that is a substrate for proteolytic degradation, correct simulations were obtained with the newly translocated protein as alternative protease substrate.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Kinetic competition between folding, degradation, and aggregation. Schematic representation of translocation (zero order rate constant, kexport), folding (first order rate constant, kfold), degradation (first order rate constant, kdeg), and aggregation reactions. In the postulated scheme, the newly translocated protein (NewP species) is assumed to have two alternative pathways: either it normally folds to give the folded protein (FoldP species) or it evolves via a side reaction (first order rate constant, kmis) leading to a misfolded protein (MisP species). Once again, a kinetic competition is thought to occur between degradation and aggregation of the misfolded protein. For the sake of simplicity, we assumed, according to Ref. 29, that the aggregation rate is limited by an initial dimerization step. Hence, it is modeled as a second order reaction (rate constant, kagg). The time evolution of this open system is governed by the following differential equations.
  <FR><NU>d[<UP>NewP</UP>]</NU><DE>dt</DE></FR>=k<SUB><UP>export</UP></SUB>−(k<SUB><UP>mis</UP></SUB>+k<SUB><UP>fold</UP></SUB>)[<UP>NewP</UP>] (Eq. 1)
<FR><NU>d[<UP>MisP</UP>]</NU><DE>dt</DE></FR>=k<SUB><UP>mis</UP></SUB>[<UP>NewP</UP>]−k<SUB><UP>deg</UP></SUB>[<UP>MisP</UP>]−k<SUB><UP>agg</UP></SUB>[<UP>MisP</UP>]<SUP>2</SUP> (Eq. 2)
The stationary concentrations [NewP]0 and [MisP]0 of the newly translocated protein and misfolded protein correspond, respectively, to the conditions d[NewP]/dt = 0 and d[MisP]/dt = 0. Thus, the steady-state of the system is given by the following equations.
[<UP>NewP</UP>]<SUB>0</SUB>=<FR><NU>k<SUB><UP>export</UP></SUB></NU><DE>k<SUB><UP>mis</UP></SUB>+k<SUB><UP>fold</UP></SUB></DE></FR> (Eq. 3)
[<UP>MisP</UP>]<SUB>0</SUB>=<FR><NU><UP>−</UP>k<SUB><UP>deg</UP></SUB>+<RAD><RCD>&dgr;</RCD></RAD></NU><DE>2k<SUB><UP>agg</UP></SUB></DE></FR> (Eq. 4)
where delta  = kdeg2 + (4kaggkmiskexport)/(kmis + kfold). Finally, the stationary fluxes of the folding, aggregation, and degradation processes are as follows, respectively.
&phgr;<SUB><UP>folding</UP></SUB>=<FR><NU>d[<UP>FoldP</UP>]</NU><DE>dt</DE></FR>=k<SUB><UP>fold</UP></SUB>[<UP>NewP</UP>]<SUB>0</SUB> (Eq. 5)
&phgr;<SUB><UP>aggregation</UP></SUB>=<FR><NU>d[<UP>AggP</UP>]</NU><DE>dt</DE></FR>=k<SUB><UP>fold</UP></SUB>[<UP>MisP</UP>]<SUB>0</SUB><SUP>2</SUP> (Eq. 6)
&phgr;<SUB><UP>degradation</UP></SUB>=<FR><NU>d[<UP>ProtP</UP>]</NU><DE>dt</DE></FR>=k<SUB><UP>deg</UP></SUB>[<UP>MisP</UP>]<SUB>0</SUB> (Eq. 7)
Numerical simulations of Equations 5, 6, and 7 show the parametric dependence of the partition between folding, aggregation, and degradation. Curves were calculated for two distinct sets of kfold and kdeg values. A, kfold = 0.1 s-1 and kdeg = 100 s-1; B, kfold = 10 s-1 and kdeg = 10 s-1, using the same values for other rate constants (kmis = 1 s-1 and kagg = 100 M-1s-1). Combination of Equations 4, 6, and 7 shows that the kexport value for which the relative predominance between aggregation and degradation fluxes becomes inverted is as follows.
k<SUB><UP>export</UP></SUB>=<FR><NU>3k<SUB><UP>deg</UP></SUB><SUP>2</SUP>(k<SUB><UP>mis</UP></SUB>+k<SUB><UP>fold</UP></SUB>)</NU><DE>4k<SUB><UP>agg</UP></SUB>k<SUB><UP>mis</UP></SUB></DE></FR> (Eq. 8)

When kmis exceeds kfold (Fig. 7A), either the degradation flux (at low kexport) or the aggregation flux (at high kexport) is larger than the flux in the folding pathway. On the contrary, when kfold is larger than kmis (Fig. 7B), the flux through the folding pathway always exceeds the rate of formation of misfolded proteins. Hence, the aggregation and degradation fluxes are both lower than the folding flux, whatever the rate of protein translocation. The relative predominance of the degradation flux over the aggregation flux depends on all the rate constant values. The degradation flux predominates at low kexport values. However, when the translocation rate increases, aggregation flux becomes more and more preferential.

This model is very similar to the general model presented by Kiefhaber et al. (26) for the kinetic competition between folding and aggregation, except for the export and degradation steps. Indeed, this outcome was incorporated into the model to support the results described here. Because kinetics of signal sequence processing of both MalE31 (11) and DegP precursors (data not shown) were unaffected by overproduction of misfolded MalE31, export to the periplasm does not constitute a critical step for the periplasmic folding pathway of bacterial proteins. The extent of aggregation is determined by both the rate of gene expression, which is related for MalE to the rate of export, and protein folding or misfolding rates. At high rates of expression, second order aggregation dominates over first order folding. Yet aggregation depends obviously on the existence of cellular proteases. At the misfolding stage a second kinetic competition between degradation and aggregation might occur, and a further increase in the rate of expression (as in the malTc background) will favor the aggregation reaction. Obviously, in pop6499 cells the degradation rate of misfolded MalE was found to be much slower than the formation of aggregated species (Fig. 1). Under these conditions, the misfolded protein escapes periplasmic degradation and accumulates as inclusion bodies. An alternative possibility to balance the relative rates of degradation versus aggregation may involve the specificity of periplasmic proteases.

Our results also suggest that the modified loop of MalE, which probably decreased the flexibility of the corresponding supersecondary structure, might promote non-native interactions of folding intermediates. Little is known about the molecular mechanism and specific groups involved in the aggregation reaction. Nevertheless, it is clear that even small changes in primary structure can drastically affect solubility, presumably by altering folding pathways (27). The proline substitution in MalE31 could explain the misfolding properties of this mutant. Indeed, the major folding effect of proline substitution is the slow cis-trans isomerization of peptidyl-proline bonds that can be a rate-determining step (28). Because MalE31 refolds more slowly than MalE-wt (Fig. 6), this slowest refolding step could be explained by a slow isomerization step in the unfolded state. However, by performing double jump experiments (28), we never detected a slow equilibrium between two unfolded states (11). Yet, we cannot rule out a fast isomerization step forming early misfolded species along the misfolding pathway. From the simulations presented in Fig. 7, we might expect that the misfolding step is faster than the slowest refolding step of MalE31. Alternatively, the aggregation of MalE31 could be interpreted as the consequence of the wrong intermolecular pairing of partially folded domains (29). Previous mutational analysis of amino acid substitutions at positions 32 and 33 (defining an alpha /beta loop in the structure of the N-domain of MalE) has identified several defective folding variants with non-Pro substitution (8). According to this explanation, mutational effects on the formation of inclusion bodies might be mediated by changes in the kinetic folding properties of the N-domain of MalE.

The heat shock response in E. coli is compartmentalized into cytoplasmic and extracytoplasmic responses that are controlled by two different sigma factors, sigma 32 and sigma E, respectively (30, 31). Misfolded proteins in the periplasm seem to be targeted only for proteolysis by triggering the sigma E degP regulon (30, 32). However, a newly translocated protein may encounter two types of rate-limiting folding steps that will be overcome by two classes of folding catalysts: protein disulfide isomerase and peptidyl prolyl cis-trans isomerases. Both classes of folding catalysts have been identified in the periplasm of E. coli. The lack of Cys residues in MalE eliminates the implication of Dsb proteins, the bacterial periplasmic protein disulfide isomerases (31). Recently, by using the cellular effect of misfolded MalE31 on the sigma E response, Missiakas et al. (12) cloned two genes, surA and fkpA, coding for two different families of peptidyl prolyl cis-trans isomerases. We may speculate that these catalysts act by accelerating a rate-limiting folding step on the productive pathway shown in Fig. 7. This possibility, which was not directly addressed in the present studies, is currently under investigation.

    ACKNOWLEDGEMENTS

We thank Dominique Missiakas for the gift of anti-DegP antibodies, Evelyne Richet for pOM82 plasmid, François Baneyx for strain SF103, Rachel Binet for pMDX plasmid, and Emett Johnson for carefully reading the manuscript.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel,: 33-01-45-68-88-32; Fax: 33-01-45-68-88-34; E-mail: jmbetton{at}pasteur.fr.

1 M. Dreyfus, unpublished results.

2 The abbreviation used is: GdnHCl, guanidine hydrochloride.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Gottesman, S., Wickner, S., and Maurizi, M. R. (1997) Genes Dev. 11, 815-823[CrossRef][Medline] [Order article via Infotrieve]
  2. Goff, S. A., and Goldberg, A. L. (1985) Cell 41, 587-595[Medline] [Order article via Infotrieve]
  3. Strauch, K., and Beckwith, J. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 1576-1580[Abstract]
  4. Strauch, K. L., Johnson, K., and Beckwith, J. (1989) J. Bacteriol. 171, 2689-2696[Medline] [Order article via Infotrieve]
  5. Lipinska, B., Fayet, O., Baird, L., and Georgopoulos, C. (1989) J. Bacteriol. 171, 1574-1584[Medline] [Order article via Infotrieve]
  6. Nikaido, H. (1994) FEBS Lett. 346, 55-58[CrossRef][Medline] [Order article via Infotrieve]
  7. Schatz, P. J., and Beckwith, J. (1990) Annu. Rev. Genet. 24, 215-248[CrossRef][Medline] [Order article via Infotrieve]
  8. Betton, J.-M., Boscus, D., Missiakas, D., Raina, S., and Hofnung, M. (1996) J. Mol. Biol. 262, 140-150[CrossRef][Medline] [Order article via Infotrieve]
  9. Spurlino, J. C., Lu, G. Y., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5202-5219[Abstract/Free Full Text]
  10. Sharff, A. J., Rodseth, L. E., Spurlino, J. C., and Quiocho, F. A. (1992) Biochemistry 31, 10657-10663[Medline] [Order article via Infotrieve]
  11. Betton, J.-M., and Hofnung, M. (1996) J. Biol. Chem. 271, 8046-8052[Abstract/Free Full Text]
  12. Missiakas, D., Betton, J.-M., and Raina, S. (1996) Mol. Microbiol. 21, 871-884[Medline] [Order article via Infotrieve]
  13. Miller, J. H. (1992) in A Short Course in Bacterial Genetics (Manual, L., ed), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  14. Shuman, H. A. (1982) J. Biol. Chem. 257, 5455-5461[Abstract/Free Full Text]
  15. Baneyx, F., and Georgiou, G. (1991) J. Bacteriol. 173, 2696-2703[Medline] [Order article via Infotrieve]
  16. Debarbouille, M., Shuman, H. A., Silhavy, T. J., and Schwartz, M. (1978) J. Mol. Biol. 124, 359-371[Medline] [Order article via Infotrieve]
  17. Richet, E. (1996) J. Mol. Biol. 264, 852-862[CrossRef][Medline] [Order article via Infotrieve]
  18. Wang, J., Betton, J.-M., Michel, V., Hofnung, M., and Charbit, A. (1997) Mol. Microbiol. 26, 1141-1143[CrossRef][Medline] [Order article via Infotrieve]
  19. Betton, J.-M., and Hofnung, M. (1994) EMBO J. 13, 1226-1234[Abstract]
  20. Duplay, P., Szmelcman, S., Bedouelle, H., and Hofnung, M. (1987) J. Mol. Biol. 194, 663-673[Medline] [Order article via Infotrieve]
  21. Ferenci, T., and Klotz, U. (1978) FEBS Lett. 94, 213-217[CrossRef][Medline] [Order article via Infotrieve]
  22. Parsell, D. A., and Sauer, R. T. (1989) J. Biol. Chem. 264, 7590-7595[Abstract/Free Full Text]
  23. Inoue, I., and Rechsteiner, I. (1994) J. Biol. Chem. 269, 29241-29246[Abstract/Free Full Text]
  24. Chan, W., Helms, L. R., Brooks, I., Lee, G., Ngola, S., Maleef, B., Hensley, P., and Wetzel, R. (1996) Folding Design 1, 77-89[Medline] [Order article via Infotrieve]
  25. Enfors, S. O. (1992) Trends Biotech. 10, 310-315[Medline] [Order article via Infotrieve]
  26. Kiefhaber, T., Rudolph, R., Kohler, H.-H., and Buchner, J. (1991) BioTechnology 9, 825-829[Medline] [Order article via Infotrieve]
  27. Mitraki, A., and King, J. (1989) BioTechnology 7, 690-697
  28. Brandts, J. F., Halvorson, H. R., and Brennan, M. (1975) Biochemistry 14, 4953-4963[Medline] [Order article via Infotrieve]
  29. Jaenicke, R. (1995) Philos. Trans. R. Soc. Lond. B Biol. Sci. 348, 97-105[Medline] [Order article via Infotrieve]
  30. Mecsas, J., Rouvière, P. E., Erickson, J. W., Donohue, T. J., and Gross, C. A. (1993) Genes Dev. 7, 2618-2628[Abstract]
  31. Missiakas, D., and Raina, S. (1997) Trends Biochem. Sci. 22, 59-63[CrossRef][Medline] [Order article via Infotrieve]
  32. Raina, S., Missiakas, D., and Georgopoulos, C. (1995) EMBO J. 14, 1043-1055[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.